- The company’s Cesium-131 based cancer treatments are effective, cheap and produce less side effects than other radiation.
- The company’s market cap is small in relation to its first big target market, prostate cancer.
- But there is another big market in treating brain cancer and a number of smaller additional applications.
- The company is displaying impressive revenue growth, margin improvement and it isn’t bleeding much cash anymore.
IsoRay Likely Has Further To Rise
December 11th, 2019 · No Comments